Organizations can better understand the maturity of AI-driven automation technology across their organization’s IT landscape through effective pharmacovigilance.
A safety surveillance strategy is a requirement for pharmaceutical companies to monitor product safety in the post-marketing environment, as well as to keep physicians informed on product risks and how to prescribe appropriately. This is usually seen as a labor-intensive cost center that often overburdens teams with work, making it difficult to retain talent. As the industry becomes more cost-conscious and is handling more real-world data sources than ever, companies are seeking ways to improve the efficiency and effectiveness of their pharmacovigilance (PV) activities. Automation offers the solution for organizations prepared to embrace it and to do the hard work required to support digital transformation.
Many reasons exist to support the adoption of automation in drug safety surveillance. Using artificial intelligence (AI) in safety surveillance can automate many aspects of the process, including non-electronic data collection, processing of inbound data, and triaging data according to its source. With these applications, companies can increase productivity, lower their technology costs, and reduce their reliance on manual labor.
Read this article in the Quality and Regulatory Sourcebook 2023
Updesh Dosanjh is a practice leader for technology solutions at IQVIA.
Pharmaceutical Technology
eBook: Quality and Regulatory
March 2023
Pages: 8-11
When referring to this article, please cite it as U. Dosanjh, "Pharmacovigilance Automation," Pharmaceutical Technology's Quality and Regulatory eBook (March 2023).
Drug Solutions Podcast: Digital Transformation in the Biopharma Industry
October 19th 2023In this episode of the Drug Solutions Podcast, industry experts discuss the challenges and advantages of the digitalization trend in the biopharma industry, with particular emphasis on the impacts to biomanufacturing.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.